ANGEL BROWN: Open Payments
NPI 1538739636 · MANNING, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$611 in 29 payments from 14 companies in 2025. Trend: 2023 $175 · 2024 $283 · 2025 $611
Food & beverage: $611
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $198 |
| Abbott Laboratories | 4 | $78 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $62 |
| Novo Nordisk Inc | 2 | $40 |
| PFIZER INC. | 2 | $40 |
| GlaxoSmithKline, LLC. | 2 | $35 |
| Merck Sharp & Dohme LLC | 2 | $32 |
| Dexcom, Inc. | 1 | $24 |
| AstraZeneca Pharmaceuticals LP | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
Products named: VRAYLAR, FREESTYLE LIBRE 3, JARDIANCE, TRELEGY ELLIPTA, VERQUVO, Dexcom G6 Transmitter, FARXIGA, PAXLOVID.
Industry payments across SC — which companies pay providers there.
